1 **Title**

- 2 Full title: Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV,
- 3 MVA-BN-Filo Ebola vaccine regimen
- 4 Short title: Helminth exposure and immune response to Ebola vaccine
- 5
- 6 Targeted journal: PLoS Neglected Tropical Diseases
- 7

8 Authors and affiliations

- 9 Houreratou Barry^{1,2}, Edouard Lhomme^{2,3,4}, Mathieu Surénaud^{4,5}, Moumini Nouctara¹, Cynthia
- 10 Robinson⁶, Viki Bockstal^{6#}, Innocent Valea^{1,7}, Serge Somda^{1,8}, Halidou Tinto^{1,7}, Nicolas
- 11 Meda^{1,9}, Brian Greenwood¹⁰, Rodolphe Thiébaut ^{2,3,4&*}, Christine Lacabaratz ^{4,5}
- 12

13 Author's affiliations

- ¹⁴ ¹ Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso
- ² Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria
- 16 SISTM team
- ³ CHU Bordeaux, Department of Medical Information, Bordeaux, France
- ⁴ Vaccine Research Institute (VRI), Créteil, France
- ⁵ Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
- 20 ⁶ Janssen Vaccines & Prevention B.V., Leiden, Netherlands
- 21 ⁷Institut de Recherche en Sciences de la Santé/Unité de Recherche Clinique de Nanoro, Burkina
- 22 Faso
- 23 ⁸Université Nazi BONI, UFR Sciences Exactes et Appliquées, Bobo-Dioulasso, Burkina Faso
- ⁹ UFR Sciences de la santé, Université joseph Ki Zerbo, Ouagadougou, Burkina Faso
- ¹⁰London School of Hygiene & Tropical Medicine (LSHTM), London, UK
- 26 [#]Current affiliation : ExeVir, Ghent, Belgium
- 27
- 28 *corresponding author (RT)
- 29 Rodolphe.thiebaut@u-bordeaux.fr
- 30
- 31 [&] These authors contributed equally

32 Abstract :

Background: The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials.

39 Methods/Principal Findings:

40 We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical

41 trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children,

42 adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d'Ivoire, Kenya, 43 Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by 44 ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and 45 Strongyloides antigens. Luminex technology was used to measure inflammatory and activation 46 markers, and Th1/Th2/Th17 cytokines at baseline. The association between binding IgG antibodies 47 specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose 48 respectively), and helminth exposure at baseline was evaluated using a multivariable linear 49 regression model adjusted for age and study group.

50 Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth 51 positive ELISA test at baseline, with differences of prevalence between studies and an increased 52 prevalence with age. The most frequently detected antibodies were those to Schistosoma mansoni 53 (10.9%), followed by Acanthocheilonema viteae (9%) and then Strongyloides ratti (7.9%). Among 54 the 41 immunological analytes tested, five were significantly (p<.003) lower in participants with 55 at least one positive helminth ELISA test result: CCL2/MCP1, FGFbasic, IL-7, IL-13 and 56 CCL11/Eotaxin compared to participants with negative helminth ELISA tests. No significant 57 association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or 58 at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies 59 at baseline.

Conclusions/Significance: No clear association was found between immune markers of helminth
 exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV/MVA BN-Filo vaccine regimen.

63 Keywords: Helminth pre-exposure; Ebola vaccine; immune response

64 Author Summary

65 Recurrent exposure to parasites may influence the immune response to vaccines, especially in 66 endemic African countries. In this study we aimed to assess the association between immune 67 markers of helminth exposure and the immune response post-vaccination with the Ad26.ZEBOV, 68 MVA-BN-Filo Ebola vaccine regimen in African and European participants who participated in 69 three international clinical trials. Seventy-eight (21.3%) of the 367 participants included in the 70 study, had at least one helminth ELISA positive test at baseline with differences of prevalence 71 between studies and an increased prevalence with increasing age. After adjustment for 72 confounding factors, the study did not show a clear association between immunological markers 73 of helminth exposure and the antibody concentration in response to the Ebola vaccine regimen.

74

75 Conflict of interest statement

Viki Bockstal and Cynthia Robinson were full-time employees of Janssen Vaccines andPrevention at the time of the study and may hold shares of Johnson & Johnson.

78

79 Data availability

80 Janssen has an agreement with the Yale Open Data Access (YODA) Project to serve as the 81 independent review panel for the evaluation of requests for clinical study reports and participant-82 level data from investigators and physicians for scientific research that will advance medical 83 knowledge and public health. Data will be made available following publication and approval by 84 YODA will be considered of any formal request with a defined analysis plan. For more information 85 on this process or to make a request, please visit the Yoda Project site at http://yoda.yale.edu. The 86 data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. 87

88

89

- 90
- 91
- -
- 92

93 Introduction

94 Since its discovery in the Democratic Republic of Congo (DRC) in 1976, the Ebola virus has 95 emerged periodically and infected people in several African countries with a high mortality and 96 morbidity rate [1]. The major outbreak of 2014-2016 in West Africa led to the acceleration of 97 vaccine development against EVD and two Ebola vaccines (the rVSV vaccine developed by Merk 98 and Ad26.ZEBOV, MVA-BN-Filo developed by Janssen) have now been prequalified by the 99 WHO and have been used in recent Ebola outbreaks [2-4].

100 Before its licensure, the heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine 101 regimen was evaluated in several clinical trials including phase 1, 2 and 2b trials in the USA, 102 Africa and Europe [5-12]. Although, the results showed the vaccine regimen to be immunogenic, 103 some geographic variabilities of the immune response were found and these variabilities are not 104 vet explained [13]. In the phase 1 trials conducted in Europe and East Africa, one year after dose 105 1 immunization, the antibody concentrations of European subjects were statistically significantly 106 higher than those of East African subjects, with the European mean value being 23% higher than 107 the East African one [13].

The observed lower level in induced immune responses in African countries compared to Europe could be explained by several factors such as human genetic, environmental, or demographic factors. One possible explanation is that recurrent exposure to the parasitic infections that are prevalent in African countries could explain such a decrease [14]. Indeed, studies in both human and animal models have shown that trematode, nematode, and *Plasmodium* infections can lead to decreased efficacy of previous vaccination and an inability to ward off new infection [15-18].

114 Helminth infections may induce a strong T helper (Th2) 2 response, in addition to inducing 115 regulatory T cells, anti-inflammatory cytokines and other mechanisms that modulate the overall 116 immune response [19-21]. A recent paper shows lower HIV-specific ADCC antibody in people 117 infected with S. mansoni [22]. Many studies have suggested that an activated immune 118 microenvironment prior to vaccination may impede the immune response to vaccines. Muyanja et 119 al [23], found in a study conducted in Entebbe, Uganda and Lausanne, Switzerland that immune 120 activation alters cellular and humoral responses to yellow fever 17D (YF-17D) vaccine in an 121 African cohort. They found that YF-17D-induced CD8+ T cell and B cell responses were 122 substantially lower in immunized individuals from Entebbe compared with immunized individuals 123 from Lausanne. The impaired vaccine response was associated with reduced YF-17D replication

and higher frequencies of exhausted and activated NK cells, differentiated T and B cell subsets
and proinflammatory monocytes suggesting an activated immune microenvironment in the
Entebbe volunteers. Another study that examined the relationship between monocytes and natural
killer cells with age, HIV infection and influenza vaccine responses showed a deleterious effect of
inflammatory monocytes on antigen-specific vaccine response in HIV infection [24].

129 In Africa, the major soil-transmitted helminth (STH) infections, hookworm (*Necator americanus* 130 and Ancylostoma duodenale), large roundworms (Ascaris lumbricoides), and whipworms 131 (Trichuris trichiura) are often co-endemic with schistosome infections, in particular Schistosoma 132 mansoni [25,26]. Since 2007, the WHO and its partners have been mobilizing resources and 133 working together to achieve control and elimination of helminths infection. Although some 134 progress has being made, the prevalence of helminth infections remains high in some parts of sub-135 Saharan Africa. Prevalence varies substantially from one country to another and also within 136 country. STH prevalence in Africa ranges between 5% to 20% and Schistosomiasis varies between 137 10% to 60% [14, 27-33].

138 There is still limited scientific evidence that exposure to helminths infections can have an impact 139 on either the immediate response to vaccination or the durability of the response, and there are no 140 data yet in the case of Ebola vaccines, though it is mainly intended for populations living in areas 141 endemic for helminth infections. Demonstrating a link between helminths infections and the 142 response to vaccine could impact vaccination programmes and raise awareness of the need for 143 better management of helminth infections in endemic countries. The main objective of this study 144 was to assess the association between the immune markers of helminth exposure at baseline to the 145 Ebola virus glycoprotein (EBOV GP) antibody concentration post-vaccination (21 days post dose 146 two and D365 post first vaccination) in African participants from clinical studies EBL2002 and 147 EBL3001 and European participants from clinical study EBL2001 who received an Ad26.ZEBOV, 148 MVA-BN-Filo vaccine regimen against Ebola virus disease. We hypothesized that the immune 149 response to the helminths could be a marker negatively associated with the response to the Ebola 150 vaccine. The secondary objectives of the study were to evaluate the association between 151 inflammatory/activation factors measured at baseline and the EBOV GP antibody concentration 152 post-vaccination and to evaluate the association between helminth infections with hyper-153 eosinophilia at baseline and EBOV GP antibody concentration post-vaccination in the same 154 population as eosinophilia is thought to be a marker of helminth infection [34].

155 Methods

156 Study design

157 We conducted a cross sectional study in a subset of participants in the EBL2001, EBL2002 and 158 EBL3001 trials in which HIV-negative participants received an active Ebola vaccine regimen 159 consisting of Ad26.ZEBOV as dose 1 followed by MVA-BN-Filo as dose 2 [5-12]. All participants 160 were HIV-negative. EBL2001 and EBL2002 were both phase 2 randomised, observer-blind, 161 placebo-controlled studies in which participants received intramuscular injections of 162 Ad26.ZEBOV, followed 28, 56 or 84 days later by MVA-BN-Filo. In the EBL2001 study 163 (ClinicalTrials.gov Identifier: NCT02416453 and EudraCT 2015-000596-27), 18 to 65 years old 164 healthy adults were included in the United Kingdom and France. The EBL2002 study 165 (ClinicalTrials.gov Identifier: NCT02564523) was conducted in Burkina Faso, Cote d'Ivoire, Kenya and Uganda and enrolled three cohorts; 18 to 70 years old healthy adults, HIV infected 166 167 adults, 12 to 17 years old adolescents and 6 to 11 years old children. The EBL3001 168 (ClinicalTrials.gov Identifier: NCT02509494) was a phase 3 double-blinded study which 169 evaluated the safety and immunogenicity of the Ad26.ZEBOV (at day 0) and MVA-BN-Filo (at 170 day 56) vaccine regimen in healthy adults, adolescents, children and toddlers in Sierra Leone.

171 The Phase 2 UK/France study (EBL2001) protocol and study documents were approved by the 172 French national Ethics Committee (CPP Ile de France III; 3287), the French Medicine Agency 173 (150646A-61), the UK Medicines and Healthcare Products Regulatory Agency (MHRA), and the 174 UK National Research Ethics Service (South Central, Oxford; A 15/SC/0211). The Phase 2 175 Kenya/Uganda/Burkina Faso/Côte d'Ivoire study (EBL2002) protocol and study documents were 176 approved by local and national independent Ethics Committees and Institutional Review Boards 177 of the participating countries. The Sierra Leonean Phase 2 study (EBL3001) protocol and study 178 documents were approved by the Sierra Leone Ethics and Scientific Review Committee, the 179 Pharmacy Board of Sierra Leone, and the London School of Hygiene & Tropical Medicine ethics 180 committee. Participants included in the present study were randomly sampled from the initial 181 clinical trials.

182 Ebola binding antibody assay

183 The Ebola binding antibody concentration was assessed as a primary or secondary endpoint of

- 184 the three studies as previously described [5-12]. EBOV GP-specific binding antibodies were
- 185 measured at all timepoints using an EBOV GP Filovirus Animal Non-Clinical Group (FANG)

- 186 enzyme-linked immunosorbent assay (ELISA) performed at Q2 Solutions (San Juan Capistrano,
- 187 CA, USA). For this substudy, IgG binding antibodies specific to EBOV GP at Day 21 post-dose
- 188 2, and on Day 365 after the first dose were the two endpoints considered.

189 Helminth ELISA testing

- 190 A subset of the remaining baseline serum samples (pre vaccination) from the three trials'
- 191 participants has been used for analysis of helminth IgG and inflammation and activation markers.
- 192 Helminth IgG was evaluated by ELISA with three commercial kits (ELISA Schistosoma mansoni,
- 193 Bordier®; ELISA Acanthocheilonema viteae, Bordier®; ELISA Strongyloïdes ratti, Bordier®) to
- 194 measure baseline IgG against the pathogens causing schistosomiasis, strongyloidiasis and filariasis
- 195 respectively (Appendix 1 table S1).
- 196 The assays were performed following manufacturer's instructions. Absorbance at 405 nm was read
- 197 using an ELISA microplate reader. Results were expressed as the ratio of the optical density (OD)
- 198 of each sample to the OD of the "threshold" sample supplied in each kit. Samples with a ratio > 1
- were considered positive. For all the ratios between 0.9 and 1.1, the measurement was repeated to confirm the result. If the result was discordant, a third replicate was performed.
- Eosinophilia was defined as a blood eosinophil count higher than 500/ mm3 and hyper eosinophilia
 as an eosinophil level higher than 1000/mm3. Eosinophil counts were available only for studies
 EBL2001 and EBL2002.

204 Inflammation/activation markers

205 Luminex technology with commercial kits (Human XL cytokine discovery premixed magnetic 206 Luminex Perf assay kit 41plex, R&D systems) was used to measure inflammatory and activation 207 markers, and Th1/Th2/Th17 cytokines at baseline prior to vaccination. The following 41 markers 208 were measured: CCL2/MCP-1, CCL4/MIP-1β, CCL19/MIP-3β, CD40L/TNFSF5, CXCL10/IP-209 10, FGF-basic, G-CSF, GRZ B, IFN-β, IL-1α/IL-1F1, IL-1-ra/IL-1F3, IL-3, IL-5, IL-7, IL-10, IL-210 13, IL-17A, B7-H1/PD-L1, TNF-a, VEGF, CCL3/MIP-1a, CCL11/Eotaxin, CCL20/MIP-3a, 211 CX3CL1/Fractalkine, EGF, Flt-3L, GM-CSF, IFN-α, IFN-γ, IL-1β/IL-1F2, IL-2, IL-4, IL-6, IL-212 8/CXCL8, IL-12p70, IL-15, IL-33, TGF-α, TRAIL, CCL5/RANTES and IL-17E/IL25. Results 213 were expressed as concentration of each analyte (pg/ml). We included results with extrapolated 214 data (data lower than the last range point, but whose concentration was still calculated by the 215 analysis software). For data below the last range point for which the concentration could not be 216 calculated (<OOR), we imputed the lowest value obtained.

217 Statistical aspects

218 Sample size

219 For the sample size calculation, we assumed a 25% prevalence of helminth exposure at baseline 220 among African participants as the ELISA could detect both past and current infections. For a 221 prevalence of 25%, a total of 28, 24 and 41 participants who had received MVA-BN-Filo at 28, 56 222 and 84 days post Ad26.ZEBOV, respectively, were needed to demonstrate a minimum difference 223 of antibody titre of 0.56 (on log-scale) between participants positive for helminths exposure 224 compared to those who were antibody negative with a statistical power of 80% and alpha risk of 225 5%. This minimum difference corresponds to the interquartile range observed at D21 post dose 2 226 in the EBL2002 study among participants who received dose 2 at D56 post dose 1. The sample 227 size calculations were performed in regards to the primary hypothesis to be tested for each study separately (see more details in Appendix 2). 228

229 Statistical analyses

230 Spearman correlations were performed between the concentration of inflammatory and activation markers measured at baseline and the EBOV GP antibody concentration 21 days post-dose 2 and 231 232 365 days post-dose 1 vaccination, respectively. The association between the immune response to 233 helminths and the levels of activation of inflammatory markers was assessed using a Student's t-234 test. The association between the immune response to helminths and eosinophil count, was 235 assessed by the Chi square test. The association between EBOV GP antibodies and eosinophil 236 count was assessed by Pearson correlation and a mean comparison of the concentration of EBOV 237 GP antibodies with normal eosinophilia (<500/mm³) or hyper-eosinophilia (level >500/mm³) was 238 performed using a Student's t-test.

239 The association between the concentration of EBOV GP antibodies 21 days post-dose 2 or 365 240 days post-dose 1, and positive ELISA for helminth exposure at baseline (ELISA S. mansoni, 241 ELISA A. viteae, ELISA S. ratti) was evaluated by study (EBL2001, EBL2002 and EBL3001), in 242 the pooled studies for any ELISA test (considered positive if at least one of the three tests was 243 positive) and for each of the three ELISA tests separately using Student's t-test. Linear regression 244 models with the log transformed concentration of EBOV GP antibodies at either 21 days post-dose 245 2 or at 365 day post-dose 1 as the dependant variable were used to adjust for potential confounding 246 factors (age group and study). We analyzed the immune response to helminth exposure as a five 247 modalities variable: no positive test (modality 1), a single positive test (modality 2-4), or multiple

248 positive tests (modality 5). All analyses were conducted using RStudio version 1.2.5033 and a p-

249 value ≤ 0.05 was considered as statistically significant.

250 **Results**

251 **Study population**

A total of 367 participants was included in the analyses: 87 (23.7%) from EBL2001, 184 (50.1%)

from EBL2002 and 96 (26.2%) from EBL3001. Study population characteristics (sex, age,

- country) are described in **Table1**.
- Table1: Description of the population included in the helminth substudy by trial (EBL2001,
 EBL2002, EBL3001)

Characteristics	Pooled studies	EBL2001	EBL2002	EBL3001
	(N = 367)	(Europe)	(East and West Africa)	(Sierra Leone)
		(N = 87)	(N = 184)	(N = 96)
Sex, n (%)				
Female	167 (45.5%)	46 (52.8%)	83 (45.1%)	38 (39.6%)
Males	200 (54.5%)	41 (47.2%)	101 (54.9%)	58 (60.4%)
Age, years				
median (Q1, Q3)	19 (10, 3)	40 (30, 5)	16 (11, 3)	10 (4, 2)
Adults, n (%)	192 (52.3%)	87 (100.0%)	81 (44.0%)	24 (25.0%)
Adolescents, n (%)	72(19.6%)	0 (0.0%)	49 (26.6%)	23 (24.0%)
Children, n (%)	103(28.1%)	0 (0.0%)	54 (29.3%)	49 (51.0%)
Country, n (%)				
France	34 (9.3%)	34 (39.1%)	-	-
United Kingdom	53 (14.4%)	53 (60.9%)	-	-
Burkina Faso	55 (15.0%)	-	55 (29.9%)	-
Cote d'Ivoire	37 (10.1%)	-	37 (20.1%)	-
Kenya	42 (11.4%)	-	42 (22.8%)	-
Uganda	50 (13.6%)	-	50 (27.2%)	-
Sierra Leone	96 (26.2%)	-	-	96 (100.0%)

258 **Prevalence of helminth exposure at baseline** 259 A total of 78 participants (21.3%) had at least one positive helminth ELISA test at baseline. 260 including 20 (5.45%) participants with at least two positive helminth ELISA tests and 4 (1.1%) 261 participants with all three helminth ELISA tests positive. S. mansoni was the most frequent 262 helminth infection detected (40 participants, 10.9%). 33 participants (9.0%) and 29 participants, 263 7.9%) had positive ELISA tests to A. viteae and S. ratti respectively. The prevalence of helminth 264 ELISA test positivity is shown in Fig 1 and Appendix 3-Table S3 265 266 Fig 1. Description of helminth ELISA tests results at baseline among the 367 participants from 267 EBL2001, EBL2002 and EBL3001 trials. 268 269 270 271 272 273 274 275 Elisasr: This line shows the 29 samples which were positive in the S. ratti ELISA test Elisaav: This line shows the 3 samples which were positive in the A. viteae ELISA test Elisasm: This line shows the 40 samples which were positive in the S. mansoni ELISA test The intersection size on the y axis shows the number of samples which were positive for the tests indicated with dots (single test) or dots and lines (multiple tests) below the x axis. Each bar shows the number of samples positive to each test taken alone and the number of samples positive to all the possible combination of the tests 276 The distribution of the type of helminth by age group, study and country is shown in **Table 2.** The 277 positive rate increased with age with 26% (50/192) of adults, 18% (13/72) of adolescents and 15% 278 (15/103) of children having at least one positive helminth ELISA test (p= 0.05). No significant 279 difference was found between males (37/200, 18%) and females (41/167, 25%) (p = 0.20). Adults 280 represented 64% of all participants with at least one positive ELISA test. More participants had at 281 least one positive helminth ELISA test in EBL2002 study (47/184, 26%) and in the EBL3001 study 282 (22/96, 23%) as compared to the EBL2001 study (9/87, 10%). The highest positive rate was found 283 in Uganda (34%) followed by Cote d'Ivoire (32%), Burkina Faso (25%) then Sierra Leone (23%). 284 The lowest rates of any positive helminth ELISA test were found in England (9.4%), Kenya 285 (9.5%), and France (12%). Results are shown in Appendix 3-Tables S4 and S5. 286 287 288 289 290 291 292 293

Table 2: Distribution of the type of helminth by age group(cohort), study and country.

295

Characteristic	None , N = 289	<i>A.viteae</i> ¹ , N = 17	<i>S.mansoni</i> ¹ , N = 27	S.ratti ¹ , N = 14	Multiple2, N = 20	Overall , N = 367
AGE GROUP, n (%)						
Children	88 (85%)	4 (3.9%)	4 (3.9%)	1 (1.0%)	6 (5.8%)	103 (100%)
Adolescents	59 (82%)	3 (4.2%)	5 (6.9%)	1 (1.4%)	4 (5.6%)	72 (100%)
Adults	142 (74%)	10 (5.2%)	18 (9.4%)	12 (6.2%)	10 (5.2%)	192 (100%)
SEX						
Female	126 (75%)	11 (6.6%)	12 (7.2%)	9 (5.4%)	9 (5.4%)	167 (100%)
Male	163 (82%)	6 (3.0%)	15 (7.5%)	5 (2.5%)	11 (5.5%)	200 (100%)
STUDY, n (%)						
EBL2001	78 (90%)	1 (1.1%)	1 (1.1%)	6 (6.9%)	1 (1.1%)	87 (100%)
EBL2002	137 (74%)	14 (7.6%)	18 (9.8%)	7 (3.8%)	8 (4.3%)	184 (100%)
EBL3001	74 (77%)	2 (2.1%)	8 (8.3%)	1 (1.0%)	11 (11%)	96 (100%)
COUNTRY, n (%)						
Burkina Faso	41 (75%)	2 (3.6%)	10 (18%)	0 (0%)	2 (3.6%)	55 (100%)
Cote Ivoire	25 (68%)	2 (5.4%)	4 (11%)	2 (5.4%)	4 (11%)	37 (100%)
France	30 (88%)	1 (2.9%)	0 (0%)	2 (5.9%)	1 (2.9%)	34 (100%)
United Kingdom	48 (91%)	0 (0%)	1 (1.9%)	4 (7.5%)	0 (0%)	53 (100%)
Kenya	38 (90%)	0 (0%)	2 (4.8%)	2 (4.8%)	0 (0%)	42 (100%)
Sierra Leone	74 (77%)	2 (2.1%)	8 (8.3%)	1 (1.0%)	11 (11%)	96 (100%)
Uganda	33 (66%)	10 (20%)	2 (4.0%)	3 (6.0%)	2 (4.0%)	50 (100%)

¹Positive ELISA test for only this specific helminth test

297 ²Multiple positive ELISA tests (a combination of at least two positive helminth ELISA tests)

298 Eosinophil level at baseline

Only 18 participants were found with eosinophilia (an eosinophil count higher than 500 cells / mm3 at baseline, all from the EBL2002 study. Among them, 9 (50%) had at least one positive helminth ELISA test. More participants with at least one positive helminth ELISA test had eosinophilia (9/55, 16.4%) than participants with negative helminth ELISA tests (9/213, 4.2%) (p = 0.003, Appendix 4 - tables S6 to S8). No association was found between EBOV-GP antibody levels and the presence of eosinophilia ($\mathbf{p} = 0.56$, Appendix 4 - Figure S1).

305

306 Inflammatory markers at baseline

307 The distributions of the inflammatory/activation markers as measured by Luminex were

- 308 significantly different between studies, with a general increase of inflammatory and activation
- 309 markers (i.e. CCL19/MIP-3β, TRAIL, CCL4/MIP-1β, CXCL10/IP-10, IL-6, IL-1ra, IL-3, IL-5,
- 310 IL-10, IL-17A, TNFa, IL-33, TGFa, CCL5/RANTES, PD-L1, VEGF, MIP-1a, MIP-3a,
- 311 CX3CL1) in African trials (EBL2002, EBL3001) as compared to the trial conducted in Europe
- 312 (EBL2001). All results are provided in supplementary Appendix 5- Figure S4.
- 313 None of the inflammatory and activation markers measured at baseline were correlated with
- EBOV GP antibody concentration, either at 21 days post dose 2 (Appendix 5 Figure S2A), or
- at 365 days post dose 1 (Appendix 5 Figure S2B). Among the 41 analytes tested, 5 were
- 316 significantly lower in participants with at least one positive helminth ELISA test compared to
- those without any positive test: IL-13 (p = 0.008), CCL11/Eotaxin (p = 0.002), IL-7 (p = 0.004),
- 318 CCL2/MCP-1 (p = 0.002), and basic FGF (p = 0.002) (Appendix 5 Figure S3).

319 EBOV-GP antibody concentration at Day 21 post-dose two

- 320 In the pooled univariable analysis (Table 3), the EBOV-GP antibody concentration 21 days post-
- 321 dose 2 was not significantly associated with any helminth ELISA tests (any Helminth, **p=0.07**).
- 322 although EBOV-GP antibody concentrations tended to be lower in participants with an A. viteae
- 323 positive ELISA test compared to those without any positive ELISA (-0.61 log units/ml, 95%
- 324 CI: -1.13 -0.09). The EBOV-GP antibody concentration at 21 days post dose 2 was significantly
- 325 different according to age groups (p = 0.002). Children had a higher EBOV-GP binding antibody
- 326 GMC at Day 21 post-dose 2 than adults ($+0.45 \log \text{unit/ml}, 95\% \text{ CI: } 0.20 0.70$).
- 327 A multivariable analysis adjusted for age group and the study was performed. There was no 328 association between helminth ELISA seropositivity and EBOV-GP antibody concentration at 21

- days post-dose 2 (p = 0.19). Age group was still associated with antibody concentration with a
- 330 higher EBOV-GP antibody concentration at 21 days post dose 2 in children compared to adults
- 331 (+0.42 log unit/ml, 95% CI: 0.12 0.73).
- 332 Table 3: Results of univariable and multivariable linear regression analysis of EBOV-GP antibody
- 333 concentration (log 10 transformed) at 21 days post dose 2 adjusted for helminth ELISA test, age
- 334 group and study

	Univariable analysis			Multivariable analysis		
Variables	Coefficient	p-value	95% CI	Coefficient	p-value	95% CI
Any helminth	-0.24	0.07	-0.51 - 0.02			
(Yes vs No)						
Helminth		0.18			0.19	
None	ref					
A. viteae	-0.61	0.02	-1.130.09	-0.60	0.02	-1.120.08
S. mansoni	-0.15	0.47	-0.57 - 0.26	-0.10	0.64	-0.53 - 0.32
S. ratti	-0.02	0.95	-0.5 - 0.55	0.11	0.70	-0.46 - 0.68
Multiple ¹	-0.22	0.37	-0.69 - 0.26	-0.22	0.37	-0.70 - 0.27
Age group		0.002			0.02	
Adults	ref			ref		
Children	0.45	0.0004	0.20 - 0.70	0.42	0.006	0.12 - 0.73
Adolescent	0.20623	0.15	-0.07 - 0.49	0.17	0.29	-0.15 - 0.49
Study		0.23			0.57	
EBL2001	ref			ref		
EBL2002	0.20	0.14	-0.07 - 0.47	0.09	0.58	-0.23 - 0.40
EBL3001	0.25	0.11	-0.05 - 0.55	0.03	0.86	-0.34 - 0.41

¹Multiple positive ELISA tests (a combination of at least two positive helminth ELISAs tests)

336 EBOV-GP antibody concentration at Day 365 post-dose 1 vaccination

The univariable and multivariable analyses of the EBOV GP antibody concentration at Day 365 found no significant association with helminth exposure (Table 4). However, age group and study were independently associated with the EBOV-GP antibody concentration. Adolescence exhibited a better response as compared to children (-0.41 log unit/ml, 95% CI: -0.73 – -0.09). Even after adjustment for helminth exposure and age, the participants included in Europe had a better response than in Africa (p<0.001).

- 343 Table 4: Results of the univariable and multivariable analysis of EBOV-GP antibody concentration
- 344 (log 10 transformed) at 365 days post-dose 1 vaccination, adjusted for helminth ELISA test, age group
- 345 and study

Variables	Univariable analysis		Multivariable analysis			
	Coefficient	p-value	95% CI	Coefficient.	p-value	95% CI
Any helminth	-0.17	0.23	-0.45 - 0.11			
(Yes vs No)						
Helminth		0.18			0.85	
None	ref			ref		
A.vitea	-0.06	0.82	-0.60 - 0.48	-0.13	0.61	-0.64 - 0.38
S. mansoni	-0.18	0.42	-0.61 - 0.26	-0.10	0.64	-0.52 - 0.32
S. ratti	0.16	0.60	-0.45 - 0.78	-0.09	0.77	-0.67 - 0.50
Multiple ¹	-0.48	0.06	-0.98 - 0.02	-0.24	0.32	-0.72 - 0.24
Age	0.01	0.003	0.004 - 0.01			
Age group		0.005			0.03	
Adults	ref			ref		
Children	-0.22	0.11	-0.49 - 0.02	0.12	0.41	-0.17 - 0.42
Adolescent	-0.52	0.001	-0.820.21	-0.28	0.08	-0.60 - 0.03
Study		< 0.001			< 0.001	
EBL2001	ref					
EBL2002	-0.50	0.003	-0.82 - 0.17	-0.44	0.02	-0.810.07
EBL3001	-1.17	< 0.001	-1.530.81	-1.15	< 0.001	-1.560.73
Country		< 0.001				
United	ref					
Kingdom						
Burkina Faso	-0.48	0.05				
Cote d'Ivoire	-0.74	0.005				
France	-0.41	0.16				
Kenya	- 0.85	0.001				
Sierra Leone	-1.37	< 0.001				
Uganda	-0.77	0.002				

¹Multiple positive ELISA tests (a combination of at least two positive helminth ELISAs)

348 **Discussion**

356

349 As expected, the prevalence of helminth exposure as indicated by detection of antibodies against

350 *S.mansoni*, *A viteae* and *S ratti* varied according to geographical location, and increased with age.

351 Helminth exposure did not impact the EBOV-GP antibody concentration post Ad26.ZEBOV,

352 MVA -BN-Filo vaccination, neither at 21 days post-dose 2, nor one-year post-dose 1.

353 The three ELISA tests used in our study allowed us to estimate exposure to the main helminths

354 responsible for schistosomiasis, soil transmitted helminth infections (*Strongyloides*) and filariasis.

355 A positive helminth ELISA test revealed the presence of antibodies against the targeted helminth

association if only recent or ongoing exposure to an helminth has an impact on the immune

species that could be the result of a recent or past exposure. Therefore, we may have missed the

358 response to the vaccine.

359 We used the eosinophil count as an indirect measure of recent exposure to helminth infection. 360 However, the prevalence of hyper-eosinophilia was very low, which is consistent with a low 361 prevalence of current or recent infection in helminth-exposed participants in our study. As many 362 pathological conditions can lead to eosinophilia, the common causes being allergies, drug reactions 363 and parasitosis, it remains an imperfect marker to evaluate a recent helminth infection. The 364 limitation of using these ELISA tests is the existence of high level of cross-reactivity between the 365 ELISA assays and with other helminths. There could be an association with a specific infection that 366 these broad-based assays might not have picked up.

Other parasites not measured in our study could also play a role in modulating the immune response in Africa such as malaria [35-38]. However, Ishola D et al [38] did not find a consistent effect of malaria infection on EBOV-GP binding antibody concentrations assessed post-dose 2 vaccination with the Ad26.ZEBOV, MVA-BN-Filo regimen in Sierra Leone, but they did observe a trend toward lower vaccine-induced antibody concentrations (GMR, 82; 95% CI, .67–1.02) in participants with malaria infection as measured by microscopy.

A majority of the activation/inflammation biomarkers quantified in this study were increased at baseline in individuals enrolled in African trials (EBL2002 and 3001) as compared to the European trial (EBL2001). This observation is consistent with what was already described in the literature [39-41]. However, we did not observe any correlation between anti-EBOV GP antibody response and any of the biomarkers measured at baseline. Other markers not quantified in this study and more specific of antibody responses, like IL-21, CXCL13, BAFF and APRIL, could be different

379	in African and European individuals. Helminth exposure, as measured in this study, did not seem
380	to be associated with activation/inflammation markers and showed a decrease of IL-13,
381	CCL11/Eotaxin, IL-7, CCL2/MCP-1 and bFGF. Thus, these results are consistent with the absence
382	of an effect of helminth exposure on the level of anti-EBOV GP antibody response observed after
383	vaccination.
384	In conclusion, the results of the present study do not suggest an association between the immune
385	response to helminths exposure and the response to the Ad26.ZEBOV, MVA-BN-Filo vaccine
386	regimen. Direct measurement of the microbiota present at the time of vaccination may provide
387	additional information on the potential factors associated with variation in the response to
388	vaccines in Africa [42].
389	
390	
391	
392	
393	
394 202	
395	Acknowledgment
396	This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under
397	grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861) and EBOVAC3
398	(grant nr.800176). This Joint Undertaking receives support from the European Union's Horizon
399	2020 research and innovation programme and the EFPIA.
400	

401 **References**

402

411

428

- Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus disease. The Lancet [Internet]. 2019 Mar [cited 2023 Feb 1];393(10174):936–48. Available from: <u>https://linkinghub.elsevier.com/retrieve/pii/S0140673618331325</u>
 World Health Organization. WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries. [cited 2021 Mar 25]. Available from:
- 409https://www.who.int/news-room/detail/12-11-2019-who-prequalifies-ebola-vaccine-410paving-the-way-for-its-use-in-high-risk-countries.
- 412 3. World Health Organization. Strategic Advisory Group of Experts (SAGE) on 413 immunization interim recommendations on vaccination against Ebola Virus 414 Disease (EVD) 7 May 2019. [cited 2021 Mar 25]. Available from: 415 <u>https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendati</u> 416 <u>ons_may_2019.pdf?ua=1.</u>
- 417
 418
 4. Vaccine against Ebola: Commission grants new market authorizations. [cited 2021 Mar 25]. Available from:
 420 <u>https://ec.europa.eu/commission/presscorner/detail/en/IP 20 1248</u>
- 421
 422
 423
 423
 423
 424
 424
 425
 425
 425
 426
 426
 427
 427
 428
 429
 429
 429
 420
 420
 420
 421
 421
 422
 423
 424
 424
 425
 425
 425
 426
 427
 427
 427
 428
 429
 429
 429
 420
 420
 420
 421
 421
 422
 423
 424
 425
 425
 426
 427
 427
 427
 428
 429
 429
 429
 420
 420
 420
 420
 421
 421
 422
 423
 424
 425
 425
 426
 427
 427
 428
 429
 429
 429
 420
 420
 420
 420
 420
 421
 421
 422
 422
 423
 424
 425
 425
 426
 427
 427
 427
 428
 429
 429
 429
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
- Anywaine Z, Barry H, Anzala O, Mutua G, Sirima SB, Eholie S, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebocontrolled, multicentre Phase II clinical trial. Beeson JG, editor. PLoS Med [Internet]. 2022 Jan 11 [cited 2023 Feb 1];19(1):e1003865. Available from: <u>https://dx.plos.org/10.1371/journal.pmed.1003865</u>
- 435
 436
 7. Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, et al. Safety and 437 immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola 438 vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled 439 Phase II clinical trial in Africa. Beeson JG, editor. PLoS Med [Internet]. 2021 Oct 440 29 [cited 2023 Feb 1];18(10):e1003813. Available from: 441 <u>https://dx.plos.org/10.1371/journal.pmed.1003813</u>
- 8. Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, et al. Safety
 and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and
 MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-

446 447 448		label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. The Lancet Infectious Diseases [Internet]. 2022 Jan [cited 2023 Feb 1]:22(1):97–109 Available from:
449 450		https://linkinghub.elsevier.com/retrieve/pii/S1473309921001250
451 452	9.	Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al. Safety
453		Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-
454 455		2023 Feb 1];22(1):110–22. Available from:
456 457		https://linkinghub.elsevier.com/retrieve/pii/S1473309921001286
458 459 460 461 462 463 464	10.	Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with ad26. Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in nairobi, kenya. The Journal of Infectious Diseases [Internet]. 2019 Jun 5 [cited 2023 Feb 1];220(1):57–67. Available from: https://academic.oup.com/jid/article/220/1/57/5364047
465 466 467 468 469 470	11.	Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, et al. Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial. JAMA [Internet]. 2016 Apr 19 [cited 2023 Feb 1];315(15):1610. Available from: <u>http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.4218</u>
471 472 473 474 475 476 477	12.	Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with ad26. Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in uganda and tanzania. The Journal of Infectious Diseases [Internet]. 2019 Jun 5 [cited 2023 Feb 1];220(1):46–56. Available from: https://academic.oup.com/jid/article/220/1/46/5364034
477 478 479 480 481 482 483	13	Pasin C, Balelli I, Van Effelterre T, Bockstal V, Solforosi L, Prague M, et al. Dynamics of the humoral immune response to a prime-boost ebola vaccine: quantification and sources of variation. Heise MT, editor. J Virol [Internet]. 2019 Sep 15 [cited 2023 Feb 1];93(18):e00579-19. Available from: https://journals.asm.org/doi/10.1128/JVI.00579-19
484 485 486 487 488 488	14	Baiden F, Fleck S, Leigh B, Ayieko P, Tindanbil D, Otieno T, et al. Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols. Luty AJF, editor. PLoS ONE [Internet]. 2022 Jul 6 [cited 2023 Feb 1];17(7):e0270968. Available from: https://dx.plos.org/10.1371/journal.pone.0270968
490 491	15.	Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. Impaired tetanus- specific cellular and humoral responses following tetanus vaccination in human

 https://academic.oup.com/jid/article-lookup/doi/10.1086/515661 f6. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific thl-like immune responses in humans infected with schistosoma mansoni. The Journal of Infectious Diseases [Internet], 1996 Jan [cited 2023 Feb 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01223292-201009000-0009 21. De Bruyn G. Cofactors that m	492 493	onchocerciasis: a possible role for interleukin-10. J INFECT DIS [Internet]. 1998 Oct [cited 2023 Feb 1];178(4):1133–8. Available from:
 16. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific thi-like immune responses in humans infected with schistosoma mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimes despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2011 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://journals.lww.com/01222929-201009000-0009 20. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma	494	https://academic.oup.com/jid/article-lookup/doi/10.1086/515661
 16. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific thl-like immune responses in humans infected with schistosoma mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2011 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAL69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Sosnko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://journals.lww.com/01222929-201009000-0009 20. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in U	495	
 specific thl-like immune responses in humans infected with schistosoma mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA- MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journa	496 16.	Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-
 mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA- MVA and MVA-gp140 Env vaccine regimens despite antihelminhic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147149220800949 20. Obuku AE, Asiki G, Abaasa A, Soonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK	497	specific thl-like immune responses in humans infected with schistosoma
 1];173(1):269–72. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA- MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Soonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in U	498	mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb
 https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA- MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-20100900-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et	499	1];173(1):269–72. Available from:
 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574–1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-20100900-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	500	https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269
 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Sonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G, Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	501	
 AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA- MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/TAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	502 17.	Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson
 MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 8. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147149220800949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-20100900-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	503	AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-
 and increases helminth-associated pathology in a mouse model. Silvestri G, editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 8. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2010 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lvw.com/01222929-201009000-00009 Cobuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	504	MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment
 editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182. Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	505	and increases helminth-associated pathology in a mouse model. Silvestri G,
 Available from: https://dx.plos.org/10.1371/journal.ppat.1007182 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	506	editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182.
 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	507	Available from: <u>https://dx.plos.org/10.1371/journal.ppat.1007182</u>
 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al. Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	508	
 Human infection with <i>ascaris lumbricoides</i> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/0122292-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	509 18.	Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al.
 interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	510	Human infection with ascaris lumbricoides is associated with suppression of the
 vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-20100900-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	511	interleukin-2 response to recombinant cholera toxin b subunit following
 Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from: https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	512	vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect
 https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	513	Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from:
 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	514	https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001
 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: <u>https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949</u> 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: <u>http://www.liebertpub.com/doi/10.1089/aid.2015.0274</u> 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: <u>http://journals.lww.com/01222929-201009000-00009</u> 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	515	
 could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	516 19.	Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that
 [cited 2023 Feb 1];24(6):243–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	517	could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun
 https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	518	[cited 2023 Feb 1];24(6):243–5. Available from:
 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	519	https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949
 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: <u>http://www.liebertpub.com/doi/10.1089/aid.2015.0274</u> 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: <u>http://journals.lww.com/01222929-201009000-00009</u> 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	520	
 <i>schistosoma mansoni</i> infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	521 20 .	Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of
 responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	522	schistosoma mansoni infection on innate and hiv-1-specific t-cell immune
 Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from: http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	523	responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human
 http://www.liebertpub.com/doi/10.1089/aid.2015.0274 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	524	Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from:
 526 527 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in 528 HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: 529 <u>http://journals.lww.com/01222929-201009000-00009</u> 530 531 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 532 responses are altered in Ugandans with schistosoma mansoni coinfection 	525	http://www.liebertpub.com/doi/10.1089/aid.2015.0274
 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: <u>http://journals.lww.com/01222929-201009000-00009</u> 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	526	
 528 HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from: http://journals.lww.com/01222929-201009000-00009 530 531 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 532 responses are altered in Ugandans with schistosoma mansoni coinfection 	527 21.	De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in
 http://journals.lww.com/01222929-201009000-00009 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection 	528	HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from:
 530 531 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 532 responses are altered in Ugandans with schistosoma mansoni coinfection 	529	http://journals.lww.com/01222929-201009000-00009
531 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1 532 responses are altered in Ugandans with schistosoma mansoni coinfection	530	
532 responses are altered in Ugandans with schistosoma mansoni coinfection	531 22.	Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1
	532	responses are altered in Ugandans with schistosoma mansoni coinfection
533 Available from: <u>https://doi.org/10.21203/rs.3.rs-2163560/v1</u>	533	Available from: <u>https://doi.org/10.21203/rs.3.rs-2163560/v1</u>
	534	
 535 23. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. 536 Immune activation alters cellular and humoral responses to yellow fever 17D 	535 23. 536	Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. Immune activation alters cellular and humoral responses to yellow fever 17D

537 538 530	vaccine. J Clin Invest [Internet]. 2014 Jul 1 [cited 2023 Feb 2];124(7):3147–58. Available from: <u>http://www.jci.org/articles/view/75429</u>
540 24 541 542 543 544 545	. George VK, Pallikkuth S, Pahwa R, de Armas LR, Rinaldi S, Pan L, et al. Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants. AIDS [Internet]. 2018 Jun 19 [cited 2023 Feb 2];32(10):1219–28. Available from: <u>https://journals.lww.com/00002030-</u> 201806190-00002
546 25 547 548 549 550	Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan africa: review of their prevalence, distribution, and disease burden. Cappello M, editor. PLoS Negl Trop Dis [Internet]. 2009 Aug 25 [cited 2023 Feb 1];3(8):e412. Available from: https://dx.plos.org/10.1371/journal.pntd.0000412
551 26 552 553 554 555 556	Karagiannis-Voules DA, Biedermann P, Ekpo UF, Garba A, Langer E, Mathieu E, et al. Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis. The Lancet Infectious Diseases [Internet]. 2015 Jan [cited 2023 Feb 1];15(1):74–84. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147330991471004
557 27 558 559 560 561 562 563	Loukouri A, Méité A, Kouadio OK, Djè NN, Trayé-Bi G, Koudou BG, et al. Prevalence, intensity of soil-transmitted helminths, and factors associated with infection: importance in control program with ivermectin and albendazole in eastern côte d'ivoire. Journal of Tropical Medicine [Internet]. 2019 Mar 24 [cited 2023 Feb 1];2019:1–10. Available from: https://www.hindawi.com/journals/jtm/2019/7658594/
564 28 565 566 567 568 569	. Ouedraogo H, Drabo F, Zongo D, Bagayan M, Bamba I, Pima T, et al. Schistosomiasis in school-age children in Burkina Faso after a decade of preventive chemotherapy. Bull World Health Organ [Internet]. 2016 Jan 1 [cited 2023 Feb 1];94(1):37–45. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709800/pdf/BLT.15.161885.pdf/</u>
570 29 571 572 573 574 575	Mangano VD, Bianchi C, Ouedraogo M, Kabore Y, Corran P, Silva N, et al. Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. Acta Tropica [Internet]. 2020 May [cited 2023 Feb 1];205:105381. Available from: <u>https://linkinghub.elsevier.com/retrieve/pii/S0001706X19303584</u>
576 30 577 578 579 580 581 581	Sang HC, Muchiri G, Ombok M, Odiere MR, Mwinzi PN. Schistosoma haematobium hotspots in south Nyanza, western Kenya: prevalence, distribution and co-endemicity with Schistosoma mansoni and soil-transmitted helminths. Parasit Vectors [Internet]. 2014 [cited 2023 Feb 1];7(1):125. Available from: http://parasitesandvectors.biomedcentral.com/articles/10.1186/1756-3305-7-125

- 31. Chadeka EA, Nagi S, Sunahara T, Cheruiyot NB, Bahati F, Ozeki Y, et al. Spatial distribution and risk factors of Schistosoma haematobium and hookworm infections among schoolchildren in Kwale, Kenya. Liang S, editor. PLoS Negl Trop Dis [Internet]. 2017 Sep 1 [cited 2023 Feb 1];11(9):e0005872. Available from: <u>https://dx.plos.org/10.1371/journal.pntd.0005872</u>
- 32. Exum NG, Kibira SPS, Ssenyonga R, Nobili J, Shannon AK, Ssempebwa JC, et
 al. The prevalence of schistosomiasis in Uganda: A nationally representative
 population estimate to inform control programs and water and sanitation
 interventions. Akullian A, editor. PLoS Negl Trop Dis [Internet]. 2019 Aug 14
 [cited 2023 Feb 1];13(8):e0007617. Available from:
 https://dx.plos.org/10.1371/journal.pntd.0007617
- 33. Bah YM, Paye J, Bah MS, Conteh A, Saffa S, Tia A, et al. Schistosomiasis in
 school age children in sierra leone after 6 years of mass drug administration with
 praziquantel. Front Public Health [Internet]. 2019 Feb 12 [cited 2023 Feb 1];7:1.
 Available from: <u>https://www.frontiersin.org/article/10.3389/fpubh.2019.00001/full</u>
- 34. Pilger D, Heukelbach J, Diederichs A, Schlosser B, Pereira Leite Costa Araújo C, Keysers A, et al. Anemia, leukocytosis and eosinophilia in a resource-poor population with helmintho-ectoparasitic coinfection. J Infect Dev Ctries [Internet].
 2010 Nov 10 [cited 2023 Feb 2];5(04):260–9. Available from: https://jidc.org/index.php/journal/article/view/21537067
 - 35. Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria: insignificant or overlooked? Expert Review of Vaccines [Internet]. 2010 Apr [cited 2023 Feb 7];9(4):409–29. Available from: http://www.tandfonline.com/doi/full/10.1586/erv.10.16
- 610
 611 36. Zimmermann P, Curtis N. Factors that influence the immune response to
 612 vaccination. Clin Microbiol Rev [Internet]. 2019 Mar 20 [cited 2023 Feb 7];32(2):
 613 e00084-18. Available from: <u>https://journals.asm.org/doi/10.1128/CMR.00084-18</u>
- 614
 615 37. Williamson WA, Greenwood BM. Impairment of the immune response to
 616 vaccination after acute malaria. The Lancet [Internet]. 1978 Jun [cited 2023 Feb
 617 7];311(8078):1328–9. Available from:
- 618 https://linkinghub.elsevier.com/retrieve/pii/S0140673678924030
- 619

594

605

606 607

608

609

38. Ishola D, The EBOVAC-Salone Malaria Infection (MALI) Sub-Study Team, Bah
OM, Bangalie FS, Bangura A, David I, et al. Asymptomatic malaria infection and
the immune response to the 2-dose ad26. Zebov, Mva-bn-filo Ebola vaccine
regimen in adults and children. Clinical Infectious Diseases [Internet]. 2022 Oct
[cited 2023 Feb 7];75(9):1585–93. Available from:
https://academic.oup.com/cid/article/75/9/1585/6595436

627	
628	39. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, et al.
629	Immunological activation markers in the serum of African and European HIV-
630	seropositive and seronegative individuals: AIDS [Internet]. 1996 Nov [cited 2023
631	Jun 2];10(13):1535–42. Available from: <u>http://journals.lww.com/00002030-</u>
632	<u>199611000-00012</u>
633	40 Oving TO Dist D. McCorrectory ID. Ecinerad EM. Technology II. Kerite D. Ctoward W.
634	40. Quinn TC, Plot P, McCormick JB, Feinsod FM, Taeiman H, Kapita B, Stevens W,
636	America and Africa. The potential role of infectious agents as cofactors in Human
637	Immunodeficiency Virus infection, JAMA, 1987 May 15: 257(19):2617-21.
638	
639	41. Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al.
640	Microbial translocation, the innate cytokine response, and HIV-1 disease
641	progression in Africa. Proc Natl Acad Sci USA [Internet]. 2009 Apr 21 [cited 2023
642	Jun 2];106(16):6718–23. Available from:
643	https://pnas.org/doi/full/10.10/3/pnas.0901983106
044 645	12 Zimmermann P. The immunological interplay between vaccination and the
646	intestinal microbiota npi Vaccines [Internet] 2023 Feb 23 [cited 2023 Jun
647	2]:8(1):24. Available from: https://www.nature.com/articles/s41541-023-00627-9
648	
649	
650	
651	
652	
653	
654	
655	
656	
657	
658	
659	
660	Supporting information
661	
662	Appendix 1: Helminth ELISA commercial kits
663	Table S1. Description of the helminth ELISA commercial kits used, measured parasitic
664	infection and cross reactivity

- 665 Appendix 2: Sample Size Calculation
- 666 Table S2. Overview of the substudy available sample selection by study (EBL2001,
- 667 EBL2002, EBL3001), age group and country.
- 668 Appendix 3: Description of helminth ELISA test results in the population
- 669 Table S3: Helminth ELISA test results at baseline among all participants of the helminth
- 670 substudy (EBL2001, EBL2002, EBL3001 pooled).
- Table S4: Characteristics of participants (pooled EBL2001, EBL2002, 3001) by helminth
- 672 ELISA test result
- 673 Table S5: Description of helminth ELISA test results in pooled EBL2001, EBL2002 and
- 674 **EBL3001 studies**
- 675 Appendix 4: Eosinophil levels at baseline
- Table S6: Description of eosinophil levels among participants from studies EBL2001,
- 677 EBL2002 and EBL3001
- 678 Table S7: Description of eosinophil levels by any helminth ELISA test among participants
- 679 from studies EBL2001 and EBL2002
- **Table S8: Description of eosinophil levels in participants with any Helminth positive**
- 681 ELISA test from EBL2001 and EBL2002 studies (N= 55)
- 682 Figure S1: Description of the EBOV-GP antibodies at 21 days post dose 2 by eosinophil
- 683 **count**
- 684 Appendix 5: Inflammatory markers
- **Figure S2: Correlation between EBOV GP binding antibody geometric mean**
- 686 concentrations (GMC) and inflammatory markers
- 687 Figure S3: Inflammatory markers (pg/mL) measured at baseline significantly associated
- 688 with helminth test positivity (0 = No positive helminth ELISA test; 1 = any positive
- 689 helminth ELISA test).
- 690 Figure S4: Inflammatory markers (pg/mL) statistically different between studies
- 691 (EBL2001, EBL2002, EBL3001) at baseline.
- 692 Appendix 6: Analysis of EBOV GP antibody concentration at 21 days post dose 2 and 365
- 693 days post dose 1.
- 694 Table S9: Robustness analyses with each helminth ELISA test separately evaluated as
- 695 independent variables at 21 days post dose 2

- 696 Table S10: Robustness analyses with each helminth ELISA test separately evaluated as an
- 697 as independent variable at 365 days post dose 1
- 698 Figure S5: Comparison of EBOV-GP antibody geometric mean concentration (log10
- 699 transformed) 21 days post dose 2 by any helminth ELISA test result at baseline in pooled
- 700 EBL2001, EBL2002, EBL3001 participants



Figure

40